Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer

Journal of the National Cancer Institute

Volumn 107, Issue 11, 2015, Pages

  Ramus, Susan J ^a   Song, Honglin ^b   Dicks, Ed ^b   Tyrer, Jonathan P ^b   Rosenthal, Adam N ^c   Intermaggio, Maria P ^a   Fraser, Lindsay ^c   Gentry Maharaj, Aleksandra ^c   Hayward, Jane ^c   Philpott, Susan ^c   Anderson, Christopher ^c   Edlund, Christopher K ^a   Conti, David ^a   Harrington, Patricia ^b   Barrowdale, Daniel ^d   Bowtell, David D ^e,f,h   Alsop, Kathryn ^e   Mitchell, Gillian ^e,g   Cicek, Mine S ^a,i   Cunningham, Julie M ⁱ   Fridley, Brooke L ^j   Alsop, Jennifer ^b   Jimenez Linan, Mercedes ^k   Poblete, Samantha ^l   Lele, Shashi ^l   Sucheston Campbell, Lara ^m   Moysich, Kirsten B ^m   Sieh, Weiva ^m   McGuire, Valerie ^m   Lester, Jenny ⁿ   Bogdanova, Natalia ^o,p   Dürst, Matthias ^q,s   Hillemanns, Peter ^r   Odunsi, Kunle ^l   Whittemore, Alice S ^m   Karlan, Beth Y ⁿ   Dörk, Thilo ^o   Goode, Ellen L ⁱ   Menon, Usha ^c   Jacobs, Ian J ^c,p   Antoniou, Antonis C ^d   Pharoah, Paul D P ^b   Gayther, Simon A ^a   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^l ADDENBROOKE S HOSPITAL   (United Kingdom)

^m ROSWELL PARK CANCER INSTITUTE   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o CEDARS SINAI MEDICAL CENTER   (United States)

^p HANNOVER MEDICAL SCHOOL   (Germany)

^q Minisrty of Health   (Belarus)

^r FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^s UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRIP1 PROTEIN; NBN PROTEIN; PALB2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; BARD1 PROTEIN, HUMAN; BRIP1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; NBN PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; RNA HELICASE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; ARTICLE; CANCER MORTALITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; NEXT GENERATION SEQUENCING; OVARY CANCER; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; AGED; CAUCASIAN; COMPARATIVE STUDY; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; NEOPLASM; OVARY TUMOR; PREDICTIVE VALUE; RISK; UNITED STATES;

ADULT; AGED; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK; RNA HELICASES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UNITED STATES;

EID: 84952641661     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv214     Document Type: Article

References (37)

1. Gayther SA, Russell P, Harrington P, et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: No evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet. 1999;65:1021-1029.
2. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
3. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012;44(5):475-476; author reply 476.
4. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879-882.
5. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104-1107.
6. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22. 2. Nat Genet. 2009;41(9):996-1000.
7. Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880-884.
8. Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42(10):874-879.
9. Permuth-Wey J, Lawrenson K, Shen HC, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21. 31. Nat Commun. 2013;4:1627.
10. Pharoah PD, Tsai YY, Ramus SJ, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013;45(4):362-370.
11. Shen H, Fridley BL, Song H, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013;4:1628.
12. Kuchenbaecker KB, Ramus SJ, Tyrer J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164-171.
13. Jervis S, Song H, Lee A, et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J Med Genet. 2014;51(2):108-113.
14. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-18037.
15. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497-506.
16. Buisson R, Dion-Cote AM, Coulombe Y, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. 2010;17(10):1247-1254.
17. Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 2013;31(1):49-57.
18. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
19. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
20. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
21. Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23(17):4703-4809.
22. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004;11(2-3):377-394.
23. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
24. Antoniou AC, Cunningham AP, Peto J, et al. The BOADiCEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98(8):1457-1466.
25. Lange K, Weeks D, Boehnke M. Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol. 1988;5(6):471-472.
26. Barnes DR, Barrowdale D, Beesley J, et al. Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer. Br J Cancer. 2013;108(12):2610-2622.
27. Shute NC, Ewens WJ. A resolution of the ascertainment sampling problem. III. Pedigrees. Am J Hum Genet. 1988;43(4):387-395.
28. Tyrer JP, Guo Q, Easton DF, Pharoah PD. The admixture maximum likelihood test to test for association between rare variants and disease phenotypes. BMC Bioinformatics. 2013;14(1):177.
29. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10(7):2473-2481.
30. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotypephenotype correlation. Nat Genet. 1995;11(4):428-433.
31. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68(2):410-419.
32. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103-105.
33. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 2002;11(4):329-336.
34. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science. 2003;302(5645):639-642.
35. Bork P, Hofmann K, Bucher P, et al. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 1997;11(1):68-76.
36. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38(11):1239-1241.
37. Mazoyer S, Dunning AM, Serova O, et al. A polymorphic stop codon in BRCA2. Nat Genet. 1996;14(3):253-254.